Analysis of the human prostate-specific proteome defined by transcriptomics and antibody-based profiling identifies TMEM79 and ACOXL as two putative, diagnostic markers in prostate cancer

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  O'Hurley, Gillian ^a,b,c   Busch, Christer ^a   Fagerberg, Linn ^d   Hallström, Björn M ^d   Stadler, Charlotte ^d   Tolf, Anna ^a   Lundberg, Emma ^d   Schwenk, Jochen M ^d   Jirström, Karin ^e   Bjartell, Anders ^f   Gallagher, William M ^b   Uhlén, Mathias ^d   Pontén, Fredrik ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c ONCOMARK LIMITED   (Ireland)

^d ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^e LUND UNIVERSITY   (Sweden)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A OXIDASE LIKE PROTEIN; MESSENGER RNA; PROTEOME; TRANSCRIPTOME; TRANSMEMBRANE PROTEIN 79; TUMOR MARKER; UNCLASSIFIED DRUG; ACYL COENZYME A OXIDASE; ACYL-COA OXIDASE-LIKE PROTEIN, HUMAN; ANTIBODY; MEMBRANE PROTEIN; TMEM79 PROTEIN, HUMAN;

ARTICLE; CANCER CELL LINE; CANCER DIAGNOSIS; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA SEQUENCE; TISSUE MICROARRAY; TRANSCRIPTOMICS; TUMOR BIOPSY; TUMOR DIFFERENTIATION; AGED; ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; PROTEOMICS; RABBIT; SEQUENCE ANALYSIS; TUMOR CELL LINE;

ACYL-COA OXIDASE; AGED; ANIMALS; ANTIBODIES; BIOMARKERS, TUMOR; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; PROTEOME; PROTEOMICS; RABBITS; RNA, MESSENGER; SEQUENCE ANALYSIS, RNA; TRANSCRIPTOME;

EID: 84941979009     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133449     Document Type: Article

References (40)

1. Brawer MK, Meyer GE, Letran JL, Bankson DD, Morris DL, Yeung KK, et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology. 1998; 52(3):372-8. Epub 1998/09/08. doi: S0090-4295(98)00241-6 [pii]. PMID: 9730446.
2. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002; 94(13):981-90. Epub 2002/07/04. PMID: 12096083.
3. Carter HB, Metter EJ, Wright J, Landis P, Platz E, Walsh PC. Prostate-specific antigen and all-cause mortality: results from the Baltimore Longitudinal Study On Aging. J Natl Cancer Inst. 2004; 96(7):557-8. Epub 2004/04/08. PMID: 15069122.
4. Carter HB. Management of low (favourable)-risk prostate cancer. BJU Int. 2011; 108(11):1684-95. Epub 2011/11/15. doi: 10.1111/j.1464-410X.2010.10489.x PMID: 22077546; PubMed Central PMCID: PMC4086468.
5. Bangma CH, Roobol MJ. Defining and predicting indolent and low risk prostate cancer. Crit Rev Oncol Hematol. 2012; 83(2):235-41. Epub 2011/10/29. doi: 10.1016/j.critrevonc.2011.10.003 PMID: 22033113.
6. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest. 1985; 76(5):1899-903. Epub 1985/11/01. doi: 10.1172/JCI112185 PMID: 3902893; PubMed Central PMCID: PMC424236.
7. Makarov DV, Loeb S, Getzenberg RH, Partin AW. Biomarkers for prostate cancer. Annu Rev Med. 2009; 60:139-51. Epub 2008/10/25. doi: 10.1146/annurev.med.60.042307.110714 PMID: 18947298.
8. Kristiansen G. Diagnostic and prognostic molecular biomarkers for prostate cancer. Histopathology. 2012; 60(1):125-41. Epub 2012/01/04. doi: 10.1111/j.1365-2559.2011.04083.x PMID: 22212082.
9. Fiorentino M, Capizzi E, Loda M. Blood and tissue biomarkers in prostate cancer: state of the art. Urol Clin North Am. 2010; 37(1):131-41, Table of Contents. Epub 2010/02/16. doi: 10.1016/j.ucl.2009.11.006 PMID: 20152526; PubMed Central PMCID: PMC3784983.
10. Ploussard G, de la Taille A. Urine biomarkers in prostate cancer. Nat Rev Urol. 2010; 7(2):101-9. Epub2010/01/13. doi: 10.1038/nrurol.2009.261 PMID: 20065953.
11. Schaefer A, Jung M, Kristiansen G, Lein M, Schrader M, Miller K, et al. MicroRNAs and cancer: current state and future perspectives in urologic oncology. Urol Oncol. 2010; 28(1):4-13. Epub 2009/01/02. doi: 10.1016/j.urolonc.2008.10.021 PMID: 19117772.
12. Duijvesz D, Luider T, Bangma CH, Jenster G. Exosomes as biomarker treasure chests for prostate cancer. Eur Urol. 2011; 59(5):823-31. Epub 2011/01/05. doi: 10.1016/j.eururo.2010.12.031 PMID: 21196075.
13. Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 2014; 13(2):397-406. Epub 2013/12/07. doi: 10.1074/mcp.M113.035600 PMID: 24309898; PubMed Central PMCID: PMC3916642.
14. Ponten F, Schwenk JM, Asplund A, Edqvist PH. The Human Protein Atlas as a proteomic resource for biomarker discovery. J Intern Med. 2011; 270(5):428-46. Epub 2011/07/15. doi: 10.1111/j.1365-2796.2011.02427.x PMID: 21752111.
15. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledgebased Human Protein Atlas. Nat Biotechnol. 2010; 28(12):1248-50. Epub 2010/12/09. doi: 10.1038/nbt1210-1248 PMID: 21139605.
16. Kampf C, Olsson I, Ryberg U, Sjostedt E, Ponten F. Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas. J Vis Exp. 2012;(63). Epub2012/06/13. doi: 3620 [pii] doi: 10.3791/3620 PMID: 22688270; PubMed Central PMCID: PMC3468196.
17. Ponten F, Jirstrom K, Uhlen M. The Human Protein Atlas-a tool for pathology. J Pathol. 2008; 216 (4):387-93. Epub 2008/10/15. doi: 10.1002/path.2440 PMID: 18853439.
18. Danielsson F, Skogs M, Huss M, Rexhepaj E, O'Hurley G, Klevebring D, et al. Majority of differentially expressed genes are down-regulated during malignant transformation in a four-stage model. Proc Natl Acad Sci U S A. 2013; 110(17):6853-8. Epub 2013/04/10. doi: 10.1073/pnas.1216436110 PMID: 23569271; PubMed Central PMCID: PMC3637701.
19. Tassidis H, Brokken LJ, Jirstrom K, Bjartell A, Ulmert D, Harkonen P, et al. Low expression of SHP-2 is associated with less favorable prostate cancer outcomes. Tumour Biol. 2013; 34(2):637-42. Epub 2012/11/30. doi: 10.1007/s13277-012-0590-1 PMID: 23192641.
20. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010; 28(5):511-5. Epub 2010/05/04. doi: nbt.1621 [pii] doi: 10.1038/nbt.1621 PMID: 20436464; PubMed Central PMCID: PMC3146043.
21. Flicek P, Amode MR, Barrell D, Beal K, Brent S, Carvalho-Silva D, et al. Ensembl 2012. Nucleic Acids Res. 2012; 40(Database issue):D84-90. Epub 2011/11/17. doi: gkr991 [pii] doi: 10.1093/nar/gkr991PMID: 22086963; PubMed Central PMCID: PMC3245178.
22. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010; 11 (10):R106. Epub 2010/10/29. doi: gb-2010-11-10-r106 [pii] doi: 10.1186/gb-2010-11-10-r106 PMID: 20979621; PubMed Central PMCID: PMC3218662.
23. RCoreTeam. R: A language and environment for statistical computing. Vienna, Austria2013.
24. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13(11):2498-504. Epub 2003/11/05. doi: 10.1101/gr.1239303 13/11/2498 [pii]. PMID: 14597658.
25. Hebenstreit D, Fang M, Gu M, Charoensawan V, van Oudenaarden A, Teichmann SA. RNA sequencing reveals two major classes of gene expression levels in metazoan cells. Mol Syst Biol. 2011; 7:497. Epub 2011/06/10. doi: 10.1038/msb.2011.28 PMID: 21654674; PubMed Central PMCID: PMC3159973.
26. Stadler C, Skogs M, Brismar H, Uhlen M, Lundberg E. A single fixation protocol for proteome-wide immunofluorescence localization studies. J Proteomics. 2010; 73(6):1067-78. Epub 2009/11/10. doi: 10.1016/j.jprot.2009.10.012 PMID: 19896565.
27. Stadler C, Hjelmare M, Neumann B, Jonasson K, Pepperkok R, Uhlen M, et al. Systematic validation of antibody binding and protein subcellular localization using siRNA and confocal microscopy. J Proteomics. 2012; 75(7):2236-51. Epub 2012/03/01. doi: 10.1016/j.jprot.2012.01.030 PMID: 22361696.
28. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledgebased Human Protein Atlas. Nat Biotechnol. 2010; 28(12):1248-50. Epub 2010/12/09. doi: nbt1210-1248 [pii] doi: 10.1038/nbt1210-1248 PMID: 21139605.
29. Uniprot. Available from: http://www.uniprot.org/uniprot/Q9BSE2.
30. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12):2893-917. Epub 2011/02/26. doi: 10.1002/ijc.25516 PMID: 21351269.
31. Issaq HJ, Waybright TJ, Veenstra TD. Cancer biomarker discovery: Opportunities and pitfalls in analytical methods. Electrophoresis. 2010; 32(9):967-75. Epub 2011/03/31. doi: 10.1002/elps.201000588 PMID: 21449066.
32. Kong HY, Byun J. Emerging Roles of Human Prostatic Acid Phosphatase. Biomol Ther (Seoul). 2013; 21(1):10-20. Epub 2013/09/07. doi: 10.4062/biomolther.2012.095 PMID: 24009853; PubMed Central PMCID: PMC3762301.
33. Gunia S, Koch S, May M, Dietel M, Erbersdobler A. Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequentradical prostatectomies. Virchows Arch. 2009; 454(5):573-9. Epub 2009/03/21. doi: 10.1007/s00428-009-0759-1 PMID: 19301031.
34. Henttu P, Vihko P. Prostate-specific antigen and human glandular kallikrein: two kallikreins of the human prostate. Ann Med. 1994; 26(3):157-64. Epub 1994/06/01. PMID: 7521173.
35. Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res. 2004; 2(5):257-80. Epub 2004/06/12. PMID: 15192120.
36. Wang H, He Z, Zhang C, Zhang L, Xu D. Transmembrane protein alignment and fold recognition based on predicted topology. PLoS One. 2013; 8(7):e69744. Epub 2013/07/31. doi: 10.1371/journal.pone.0069744 PMID: 23894534; PubMed Central PMCID: PMC3716705.
37. Ng DP, Poulsen BE, Deber CM. Membrane protein misassembly in disease. Biochim Biophys Acta. 2012; 1818(4):1115-22. Epub 2011/08/16. doi: 10.1016/j.bbamem.2011.07.046 PMID: 21840297.
38. Klabunde T, Hessler G. Drug design strategies for targeting G-protein-coupled receptors. Chembiochem. 2002; 3(10):928-44. Epub 2002/10/04. doi: 10.1002/1439-7633(20021004)3:10〈928::AIDCBIC928〈3.0.CO;2-5 PMID: 12362358.
39. NCBI Aceview. Available from: http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?db=human&c=Gene&l=ACOXL.
40. Hong MG, Karlsson R, Magnusson PK, Lewis MR, Isaacs W, Zheng LS, et al. A genome-wide assessment of variability in human serum metabolism. Hum Mutat. 2013; 34(3):515-24. Epub 2013/01/03. doi: 10.1002/humu.22267 PMID: 23281178.